167 related articles for article (PubMed ID: 33235818)
1. Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2].
Takeuchi S; Kagabu M; Shoji T; Nitta Y; Sugiyama T; Sato J; Nakamura Y
Oncoimmunology; 2020 Nov; 9(1):1838189. PubMed ID: 33235818
[TBL] [Abstract][Full Text] [Related]
2. Phase I Study of Multiple Epitope Peptide Vaccination in Patients With Recurrent or Persistent Cervical Cancer.
Hasegawa K; Ikeda Y; Kunugi Y; Kurosaki A; Imai Y; Kohyama S; Nagao S; Kozawa E; Yoshida K; Tsunoda T; Nakamura Y; Fujiwara K
J Immunother; 2018 May; 41(4):201-207. PubMed ID: 29432282
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study of Peptide-cocktail vaccination with tegafur-uracil/leucovorin for advanced colorectal cancer].
Sugiura F; Inoue K; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1760-2. PubMed ID: 23267878
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients.
Iinuma H; Fukushima R; Inaba T; Tamura J; Inoue T; Ogawa E; Horikawa M; Ikeda Y; Matsutani N; Takeda K; Yoshida K; Tsunoda T; Ikeda T; Nakamura Y; Okinaga K
J Transl Med; 2014 Apr; 12():84. PubMed ID: 24708624
[TBL] [Abstract][Full Text] [Related]
5. [Treatment outcome of peptide vaccination for advanced colorectal cancer].
Sugiura F; Inoue K; Kogita A; Yoshioka Y; Hida J; Okuno K; Sukegawa Y
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1584-6. PubMed ID: 24393856
[TBL] [Abstract][Full Text] [Related]
6. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer.
Higashihara Y; Kato J; Nagahara A; Izumi K; Konishi M; Kodani T; Serizawa N; Osada T; Watanabe S
Int J Oncol; 2014 Mar; 44(3):662-8. PubMed ID: 24398900
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: A phase I clinical trial.
Akazawa Y; Hosono A; Yoshikawa T; Kaneda H; Nitani C; Hara J; Kinoshita Y; Kohashi K; Manabe A; Fukutani M; Wakabayashi M; Sato A; Shoda K; Shimomura M; Mizuno S; Nakamoto Y; Nakatsura T
Cancer Sci; 2019 Dec; 110(12):3650-3662. PubMed ID: 31571332
[TBL] [Abstract][Full Text] [Related]
9. MELK expression in ovarian cancer correlates with poor outcome and its inhibition by OTSSP167 abrogates proliferation and viability of ovarian cancer cells.
Kohler RS; Kettelhack H; Knipprath-Mészaros AM; Fedier A; Schoetzau A; Jacob F; Heinzelmann-Schwarz V
Gynecol Oncol; 2017 Apr; 145(1):159-166. PubMed ID: 28214016
[TBL] [Abstract][Full Text] [Related]
10. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
Ressing ME; van Driel WJ; Brandt RM; Kenter GG; de Jong JH; Bauknecht T; Fleuren GJ; Hoogerhout P; Offringa R; Sette A; Celis E; Grey H; Trimbos BJ; Kast WM; Melief CJ
J Immunother; 2000; 23(2):255-66. PubMed ID: 10746552
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
[TBL] [Abstract][Full Text] [Related]
13. [Clinical trial of a seven-peptide vaccine and tegafur-uracil/leucovorin as combination therapy for advanced colorectal cancer].
Inoue K; Sugiura F; Kogita A; Yoshioka Y; Sukegawa Y; Hida J; Okuno K
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1276-9. PubMed ID: 25335716
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific immunotherapy of cervical and ovarian cancer.
Hung CF; Wu TC; Monie A; Roden R
Immunol Rev; 2008 Apr; 222():43-69. PubMed ID: 18363994
[TBL] [Abstract][Full Text] [Related]
15. The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer.
Kobayashi M; Chiba A; Izawa H; Yanagida E; Okamoto M; Shimodaira S; Yonemitsu Y; Shibamoto Y; Suzuki N; Nagaya M;
J Ovarian Res; 2014 May; 7():48. PubMed ID: 25298213
[TBL] [Abstract][Full Text] [Related]
16. Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites.
Morisaki T; Hikichi T; Onishi H; Morisaki T; Kubo M; Hirano T; Yoshimura S; Kiyotani K; Nakamura Y
Immunol Invest; 2021 Jul; 50(5):562-579. PubMed ID: 32660279
[TBL] [Abstract][Full Text] [Related]
17. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers.
Tsuda N; Mochizuki K; Harada M; Sukehiro A; Kawano K; Yamada A; Ushijima K; Sugiyama T; Nishida T; Yamana H; Itoh K; Kamura T
J Immunother; 2004; 27(1):60-72. PubMed ID: 14676634
[TBL] [Abstract][Full Text] [Related]
18. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients.
Kawano K; Tsuda N; Matsueda S; Sasada T; Watanabe N; Ushijima K; Yamaguchi T; Yokomine M; Itoh K; Yamada A; Kamura T
Immunopharmacol Immunotoxicol; 2014 Jun; 36(3):224-36. PubMed ID: 24773550
[TBL] [Abstract][Full Text] [Related]
19. The forkhead box M1 transcription factor as a candidate of target for anti-cancer immunotherapy.
Yokomine K; Senju S; Nakatsura T; Irie A; Hayashida Y; Ikuta Y; Harao M; Imai K; Baba H; Iwase H; Nomori H; Takahashi K; Daigo Y; Tsunoda T; Nakamura Y; Sasaki Y; Nishimura Y
Int J Cancer; 2010 May; 126(9):2153-63. PubMed ID: 19688828
[TBL] [Abstract][Full Text] [Related]
20. High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo.
Ikeda Y; Sato S; Yabuno A; Shintani D; Ogasawara A; Miwa M; Zewde M; Miyamoto T; Fujiwara K; Nakamura Y; Hasegawa K
J Gynecol Oncol; 2020 Nov; 31(6):e93. PubMed ID: 33078598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
